Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.490
-0.060 (-2.35%)
Dec 20, 2024, 4:00 PM EST - Market closed
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 4.40, with a low estimate of 3.00 and a high estimate of 7.50. The average target predicts an increase of 76.71% from the current stock price of 2.49.
Analyst Consensus: Buy
* Price targets were last updated on Nov 19, 2024.
Analyst Ratings
The average analyst rating for AKYA stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 4 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 4 | 4 | 4 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +20.48% | Nov 19, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +100.80% | Nov 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $3.5 | Strong Buy | Maintains | $6 → $3.5 | +40.56% | Nov 15, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +60.64% | Aug 13, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $4 → $3 | Buy → Hold | Downgrades | $4 → $3 | +20.48% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
83.61M
from 96.63M
Decreased by -13.48%
Revenue Next Year
93.43M
from 83.61M
Increased by 11.76%
EPS This Year
-1.12
from -1.43
EPS Next Year
-0.63
from -1.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 87.4M | 98.7M | 117.6M | |||
| Avg | 83.6M | 93.4M | 107.7M | |||
| Low | 78.9M | 87.2M | 90.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -9.6% | 18.1% | 25.9% | |||
| Avg | -13.5% | 11.8% | 15.3% | |||
| Low | -18.4% | 4.3% | -2.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.96 | -0.46 | -0.36 | |||
| Avg | -1.12 | -0.63 | -0.45 | |||
| Low | -1.13 | -0.70 | -0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.